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Abstract
Randomized evidence for aspirin in the primary prevention of cardiovascular disease (CVD)
among women is limited and suggests at most a modest effect for total CVD. Lack of compliance,
however, can null-bias estimated effects. We used marginal structural models (MSMs) to estimate
the etiologic effect of continuous aspirin use on CVD events among 39,876 apparently healthy
female health professionals aged 45 years and older in the Women’s Health Study, a randomized
trial of 100 mg aspirin every other day versus placebo. As-treated analyses and MSMs controlled
for time-varying determinants of aspirin use and CVD. Predictors of aspirin use differed by
randomized group and prior use and included medical history, CVD risk factors, and intermediate
CVD events. Previously reported intent-to-treat analyses found small non-significant effects of
aspirin on total CVD (hazard ratio (HR) =0.91, 95% confidence interval (CI) =0.81–1.03) and
CVD mortality (HR=0.95, 95% CI=0.74–1.22). As-treated analyses were similar for total CVD
with a slight reduction in CVD mortality (HR=0.88, 95%CI=0.67–1.16). MSMs, which adjusted
for non-compliance, were similar for total CVD (HR=0.93; 95% CI: 0.81, 1.07) but suggested
lower CVD mortality with aspirin use (HR = 0.76; 95% CI: 0.54, 1.08). Adjusting for non-
compliance had little impact on the estimated effect of aspirin on total CVD, but strengthened the
effect on CVD mortality. These results support a limited effect of low-dose aspirin on total CVD
in women, but potential benefit for CVD mortality.
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Introduction
Aspirin has long been known to be effective in treating acute evolving myocardial infarction
(MI) and in the secondary prevention of cardiovascular disease (CVD) [1]. A meta-analysis
of secondary prevention trials suggested a relative risk reduction of 15% in vascular
mortality and of 30% in nonfatal cardiovascular events among those assigned to aspirin use
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following a cardiovascular event. Trials of primary prevention with aspirin, however, have
been less definitive, with some suggesting a strong benefit, especially for coronary heart
disease (CHD) [2–4] and others suggesting little benefit for myocardial infarction, with
conflicting results for stroke [5,6]. A recent meta-analysis found an overall 12% reduction in
any serious vascular event [7].
The Women’s Health Study (WHS), the largest trial of aspirin for primary prevention
among women to date, tested the effect of aspirin among 39,876 female health professionals
found no effect on the composite endpoint of major cardiovascular disease, which included
MI, stroke, and CVD mortality. Based on accumulated evidence, the US Preventive Services
Task Force strongly recommended in 2002 that clinicians consider aspirin use for all adults
at increased risk of CHD or stroke, including postmenopausal women and those with CVD
risk factors [8]. Development of less extreme indicators of cardiovascular risk, such as
hypertension, diabetes, angina, transient ischemic attack (TIA), and revascularization
procedures, may prompt some to begin aspirin use. Thus, women who take aspirin may be at
higher risk of CVD due to a host of underlying risk factors and behaviors. Some of these
intermediate events may also be in the causal pathway from aspirin to CVD, leading to
complex associations among aspirin, intervening events, and CVD.
Confounding by such time-varying factors that are also affected by exposure can bias the
estimated intent-to-treat effect, and usual as-treated analyses cannot correct for this type of
bias. Marginal structural models (MSMs) [9] can be used to effectively adjust for time-
varying confounding by nonfatal CVD events which are also affected by aspirin use. Such
models can incorporate a host of intervening variables, and have been previously used to
adjust for post-MI use of aspirin in an analysis of aspirin and CVD mortality in the
Physician’s Health Study (PHS) [10]. This paper presents an analysis adjusting for time-
varying noncompliance to aspirin use due to intervening events within the WHS. In contrast
to the PHS, the primary endpoint of the WHS was incident CVD, with CVD mortality
serving as a secondary endpoint. The aim of this analysis was to determine whether control
for less serious time-varying CVD risk factors, such as angina, TIA, and revascularization




The WHS was a randomized trial of aspirin (100 mg of aspirin taken every other day) and
vitamin E (600 IU every other day) in the primary prevention of cardiovascular disease and
cancer. Detailed descriptions of the trial and its results have been published elsewhere
[6,11]. Briefly, women were eligible if they were aged 45 years or higher, had no history of
CVD or cancer, agreed to avoid taking outside aspirin or vitamin E, and remained compliant
to pill taking during a three-month placebo run-in period. A total of 39,876 female health
professionals were randomized in 1993–1996 to aspirin and/or vitamin E in a two-by-two
factorial design with four study groups defined as aspirin only, vitamin E only, both, or
neither. The trial was approved by the Institutional Review Board of Brigham and Women’s
Hospital and monitored by an external Data and Safety Monitoring Board.
Every 12 months, women were sent an annual supply of study pills supplied in monthly
calendar packs, along with a study questionnaire on compliance, side effects, risk factors
and medical events. Self-reported height and weight were collected, as well as blood
pressure and cholesterol level. Hypertension was defined as a blood pressure of at least
140/90 mmHg or on anti-hypertensive medication. High cholesterol was defined as total
cholesterol of at least 240 or self-reported physician-diagnosed high cholesterol. Family
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history of MI was defined as parental history prior to age 60. Follow-up continued until the
scheduled end of the trial in March, 2004. Morbidity and mortality follow-up were 97.2%
and 99.4% complete, respectively.
On each questionnaire, women were asked about study pill use (aspirin or aspirin placebo)
since the last questionnaire. The amount of reported aspirin use tended to have a U-shaped
distribution, with most participants taking it either nearly every other day as assigned or
taking very little if any. For these analyses, compliance to aspirin use was defined as use on
at least 120 days per year.
Study endpoints were confirmed by a blinded Endpoints Committee of physicians following
review of medical records. The primary CVD endpoint for the trial was a composite of first
major cardiovascular event that included MI, stroke, or CVD death. Individual components
of this served as secondary endpoints for the trial. Information was also collected and
reviewed on coronary revascularization procedures, (bypass surgery (CABG) or
percutaneous coronary angioplasty (PTCA)), transient ischemic attacks (TIA) and total
mortality. Written informed consent was requested to obtain related medical records
following a report of one of these events by the participant, a family member, or postal
authorities. Reports were confirmed if they passed established clinical criteria.
Statistical analysis
As the first step of analysis, logistic models predicting observed aspirin use, including both
study and outside use, were fit as a function of past aspirin use, intervening factors, and
baseline variables. The data were broken up by time (year), and pooled over time using the
counting process method [15]. We considered as candidates intermediate cardiovascular
conditions, such as angina, TIA, or revascularization; intermediate risk factors for
cardiovascular disease, such as blood pressure and cholesterol levels; markers for healthy
behavior, such as exercise, smoking, alcohol use and diet; and side-effects of aspirin or other
medical factors, such as gastrointestinal symptoms. Because the aim was to reduce bias due
to variables in the causal pathway, we included in the final models only those that were
known determinants of CVD or that were observed to be associated with CVD among
women in the placebo group. Predictors of aspirin use differed by randomized aspirin
assignment and aspirin use in the previous year; we thus fit separate models for groups
defined by these variables.
The final MSM used weighted pooled logistic regression to estimate the hazard ratio [17].
Additional detail may be found in the supplementary material. The predicted probability of
aspirin use was computed from the model for observed aspirin use described above and used
as the denominator of the weights in the MSMs. To stabilize the weights and reduce their
variability, the numerator of the weights consisted of predicted probability from a second
logistic model for observed aspirin as a function of past aspirin use and a subset of baseline
variables, without including intervening factors [16]. Because the weights can induce
correlation between the observations in a person over time, robust standard errors were
computed using the SAS procedure GENMOD.
The primary analysis used the main study endpoint of major cardiovascular disease,
including MI, stroke, and CVD mortality. Subsequent analyses were conducted using the
secondary component endpoints. Intervening events were defined differently for each
endpoint (for example, MI and stroke are intervening events in the analysis of CVD
mortality), and weights were reconstructed for each endpoint separately. All models for
CVD adjusted for age at randomization and race/ethnicity with terms in the model, except in
analyses of cardiovascular mortality which adjusted only for age due to small numbers of
CVD deaths within racial groups. For comparison with these models we also conducted
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intent-to-treat and as-treated analyses using unweighted pooled logistic models. SAS version
9.2 (SAS Institute, Cary, North Carolina) was used for all analyses.
Results
At the time of randomization, women were aged 55 years on average, 54 percent were
postmenopausal, 26% reported hypertension at baseline, and 30% reported elevated
cholesterol. A total of 19,934 women were assigned to active aspirin and 19,942 to placebo
aspirin. Baseline characteristics were balanced over aspirin intervention groups as reported
previously [6]. Over an average 10 year follow-up, 999 women reported a major
cardiovascular event, which included 391 MIs and 487 strokes. There were 246 deaths with
a confirmed cause of cardiovascular disease.
Compliance to white study pills (aspirin or aspirin placebo) tended to diminish as follow-up
continued. Compliance to study pills was excellent during the first year for both agents, with
approximately 88% taking at least two-thirds of their study aspirin or aspirin placebo at the
end of the first year. Use of study aspirin or placebo declined to 76% at five years of follow-
up and to 67% by ten years of follow-up, with an average of 73% throughout the trial.
Compliance was slightly but significantly lower in the active vs. placebo aspirin groups,
with proportions averaging about one percent lower from 24 months onward. While
participants were asked to avoid use of any other aspirin or aspirin-containing medications,
outside use aspirin for four or more days per month averaged 12% over the length of follow-
up, with no significant difference by randomized aspirin assignment.
Predictors of aspirin use
Several factors strongly predicted aspirin use, including demographics, epidemiologic risk
factors, intervening cardiovascular risk factors, and other medical conditions. The strongest
predictors were randomized assignment and aspirin use in previous years. Overall 94% of
those in the randomized aspirin group who had used aspirin in the previous year (ASAt-1)
continued to use it in the current year (ASAt), while only 18% of those who had stopped
using it began to take aspirin. In the placebo group, among those who were not taking
outside aspirin in the previous year, only 3% began to take outside aspirin in the current
year. Among those who were taking it already, 71% continued to do so. In addition, aspirin
use two years ago (ASAt-2) had a continued effect on use in the current year.
The associations of standard epidemiologic risk factors with aspirin use are shown in Table
1. These tended to differ by randomized group as well as previous use of aspirin. In the
placebo group, the use of aspirin generally increased with age. Among those in the active
aspirin group, age had a nonlinear association with compliance and was estimated using a
quadratic term. The peak age of compliance was near age 60 years. Among those
randomized to placebo, those who were taking multivitamins, were current smokers, or had
hypertension or high cholesterol tended to take outside aspirin regardless of prior use. In
contrast, among those randomized to active aspirin, those who were using aspirin already
were less likely to continue if they were smokers or had hypertension or high cholesterol.
Those who had stopped using study aspirin were more likely to begin taking aspirin if they
were taking multivitamins, used alcohol at least once a week, or had hypertension, high
cholesterol or a family history of MI prior to age 60.
Aspirin use was strongly affected by intervening cardiovascular conditions. In the placebo
group, those who experienced intervening CHD, such as angina and revascularization, a
TIA, or other cardiovascular condition were more likely to go on or stay on outside aspirin,
with stronger influence among those taking aspirin already. In the active aspirin group, the
effects differed strongly by previous use. Those using aspirin were more likely to stop when
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these conditions occurred; those not using aspirin were more likely to start using it. The
same patterns tended to be true for diabetes and migraine.
Aspirin and cardiovascular disease
Intent-to-treat analyses using pooled logistic regression found no significant effect of
randomized aspirin assignment on incidence of the composite endpoint of major CVD
((hazard rate ratio (RR) = 0.91, 95% confidence interval (CI) = 0.80, 1.03, P=0.12) (Table
2). When adjustment was made for cardiovascular risk factors and the intervening events
shown in Table 1, there was no change in the estimate. As-treated analyses using actual
observed aspirin use during the trial showed an effect closer to the null. Adjusting for the
intermediate risk factors and events had little impact.
Treatment weights for the major CVD endpoint were constructed using the logistic
regression results shown in Table 1, which served as the denominators of the weights. The
numerators were created from similar models including year, age, race and previous aspirin
use only. Censoring weights were constructed using the same terms, but showed little
variability, ranging only from 0.83 to 1.39. After multiplication of treatment and censoring
weights, the mean weight was 1.005, with a median of 0.999 (interquartile range of 0.967 to
1.009). The weights were truncated at the 0.01th and 99.99th percentiles, representing values
of 0.022 and 6.914. Censoring weights were constructed that predicted the probability of
censoring prior to the administrative end of the study in March 2004. These two sets of
weights were multiplied and accumulated over time to form the inverse probability weights.
The marginal structural model also found no overall association of aspirin use with
incidence of major CVD. The RR was 0.93 with a CI based on the robust standard error of
0.81, 1.07 (P=0.32).
The secondary endpoints of MI, stroke and cardiovascular mortality were analyzed
separately. New weights were constructed using intervening events that were not part of the
outcome. In the analysis of MI, stroke was an intervening event, and vice versa. For CVD
mortality, both MI and stroke were considered intervening events. The distributions of
weights for these outcomes were similar to those for major CVD. The pooled logistic intent-
to-treat analysis showed no effect of randomized aspirin on MI, but an 18% reduction in
stroke (P=0.03) (Table 3). The estimated effects in the MSMs tended to replicate this, but
the latter analysis tended to be more variable and less significant for stroke, likely due to the
variability introduced by the weighting.
The analysis of cardiovascular mortality, however, found different results by type of
analysis (Table 3). There was no effect of randomized aspirin on CVD mortality in the
pooled logistic intent-to-treat analysis (RR = 0.95, 95% CI: 0.74, 1.22, P=0.67). The as-
treated analysis found a small non-significant 12% reduction after controlling for other
intervening factors. The marginal structural model found a sizeable 24% reduction in risk
that remained non-significant with a wide confidence interval (95% CI: 0.54, 1.08, P=0.13).
Additional analyses considered the amount of aspirin use rather than treating it as a
dichotomous exposure. Weights were formed using polychotomous logistic regression with
aspirin use categories of none, 1–166 days per year, and at least 167 days per year. The latter
corresponds to nearly complete use of the study aspirin which is taken every other day. The
results remained null in both as-treated and marginal structural models (Table 4), although
there was a suggested dose-response effect for CVD mortality in the MSM.
Finally, pooled logistic intent-to-treat analyses suggested a difference in effect by age at
randomization, with a significant 23% reduction in the composite endpoint of major CVD
among those aged 65 or older at randomization (RR = 0.77, 95% CI: 0.62, 0.96, P=0.02)
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(Table 5). This result was replicated in both the as-treated and marginal structural analyses,
with a significant interaction with age. For those aged 65 or older, the estimated effect in the
MSM was a 27% reduction in major CVD. Similar effect modification was seen in the
analysis of CVD mortality. Although the interaction with age was not statistically
significant, the estimated reduction in CVD mortality was also stronger in those over age 65.
Discussion
Since the completion of trials in secondary prevention [1], aspirin has been in wide use
following a cardiovascular event. Following the results of the PHS and other trials [18], it
has been used increasingly in primary prevention. Indications for aspirin have continued to
expand following release of the US Preventive Services Task Force reports advocating use
for those with risk factors for CVD [8,19]. Such use, however, can serve as a confounder of
continued aspirin use even in trials where initial aspirin use is assigned randomly. As in the
PHS, in the WHS we found that prior use, cardiovascular risk factors and, especially,
intervening cardiovascular conditions strongly influenced aspirin use during the trial in both
active and placebo aspirin groups.
The published intent-to-treat analysis of the WHS data found no significant effect of
randomized aspirin assignment on incidence of the composite endpoint of major CVD ((RR
= 0.91, 95% CI = 0.80, 1.03, P=0.13) [6]. As-treated and marginal structural analyses
generally tended to replicate the intent-to-treat analysis for incidence of major CVD in these
data. Results remained null regardless of the strong effects of intermediate variables such as
angina and TIA on aspirin use. The same was true for the secondary outcome of MI, while
results for stroke continued to suggest a reduction in risk. When CVD mortality was the
outcome, however, a decreased risk was seen in the MSM analysis, although not statistically
significant. Results were strikingly similar to those seen in the PHS (Table 6). In the male
physicians, the intent-to-treat effect on CVD mortality was null, but a 26% reduction in
CVD mortality was seen using a MSM [10], similar to that seen in the WHS. Combining
these two trials suggests an overall 25% reduction in CVD mortality with aspirin use
(RR=0.75, 95% CI = 0.57–0.99, p=0.04).
It is possible that the MSM results are stronger for CVD mortality than for CVD incidence
due to the nature and impact of the intervening events. To be a time-varying confounder in
the causal pathway, the factor has to a) be a predictor of subsequent aspirin use, b) be
affected by past use, and c) be an independent determinant of the outcome. In the analysis of
incident CVD most of the factors in Table 1 predict subsequent aspirin use and are also
known or suspected risk factors for incident cardiovascular disease. They may not, however,
be affected by previous aspirin use. While TIA showed some association with randomized
aspirin in the trial (RR=0.78, 95% CI = 0.64–0.94, p=0.01) [6], revascularization procedures
[6], diabetes [20], and migraine [21] did not. Many of the other intervening cardiovascular
conditions are likely not strongly affected by aspirin use, including angina and other
cardiovascular surgeries. Thus the link between prior aspirin use and CV risk factors is not
present for CVD incidence, and the MSM analysis leads to results similar to the intent-to-
treat and as-treated analyses.
In the analysis of CV mortality, however, the intervening events of MI or stroke are included
in the weights and can be heavily influenced by previous aspirin use. In the PHS, aspirin
strongly influenced the outcome of MI, and in the WHS, aspirin influenced the outcome of
stroke. Both events strongly affect CVD mortality as well as subsequent use of aspirin. They
are thus time-varying confounders influenced by exposure. Adjusting for intermediate MI or
stroke in the as-treated analyses does not lead to as strong an effect. Using IPW more
completely adjusts for differences in aspirin use following MI or stroke that may be
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unbalanced by other CV risk factors. The strengthening of results for CVD mortality in the
MSM analysis is due to both intervening events and subsequent non-compliance.
Other analyses of these data suggest that the effect may be somewhat dose-related, at least in
terms of days taken. Although not significant, the reduction seemed stronger in those who
were taking aspirin at least 167 days per year. We were unable to directly analyze the effects
of aspirin dose, however. The PHS used a dose of 325 mg every other day, while the WHS
used a dose of 100 mg every other day. It is thus impossible to separate whether any
differences in effects seen in the two trials are due to gender or dose. It is also possible that
dose played a role in the present analyses. When individuals experience an MI or stroke,
they are likely to take aspirin at a higher dose than that used in the WHS. Because
confounding by dose is nearly complete, however, it is impossible to separate the effects of
differing doses even using MSM models.
Other limitations of these analyses must be considered. These include self-reported
measures of compliance as well as many of the intermediate risk factors. The main analyses
assume proportionality of effects over time in the survival models and thus report the
average effects over the study period. In addition, any attempts to suggest causality rely on
the assumption of no unmeasured confounding and on the correct modeling of the treatment
and censoring weights.
These analyses thus support the limited effects found in the intent-to-treat analysis for CVD
morbidity. The effects of intermediate variables on aspirin use, or more likely, the effects of
aspirin on the intermediate variables, were not sufficient to alter conclusions. Results for
CVD mortality, however, were strengthened in the adjusted analyses. As for men, a serious
nonfatal event such as an MI or stroke could be affected by previous aspirin use and could
also lead to future aspirin use. Adjusting for such effects suggests an approximate 25%
reduction in CVD mortality with continued aspirin use vs. continued nonuse. The analyses
of CVD mortality reflect the effects of aspirin in both primary prevention for incident CVD
and in secondary prevention for CVD mortality, where it has been shown to be effective in
women as well as men. Lingering questions concern the effects of duration of use versus
effects in secondary prevention. Whether a strategy of starting aspirin only after a CVD
event, or the development of serious risk factors, is the most appropriate one for women
remains to be determined.
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Table 2
Estimated Effects of Aspirin on the Combined Primary Endpoint of Major CVD, Including MI, Stroke, and
Cardiovascular Mortality.
RR CI P
Published ITT 0.91 0.80, 1.03 0.13
ITT Logistic
Crudea 0.905 0.799, 1.025 0.12
Adjusted 0.908 0.797, 1.034 0.15
As-Treated
Crude 1.004 0.885, 1.138 0.96
Adjusted 0.956 0.838, 1.091 0.51
MSM
GEE 0.932 0.812, 1.071 0.32
a
Crude = adjusted for age and race. Adjusted models control for time-varying risk factors and intervening events as specified in Table 1.
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Table 3




Published ITT 1.02 0.84, 1.25 0.83
Crude ITT Logistic 1.016 0.832, 1.240 0.88
Adjusted As-Treated 1.110 0.901, 1.367 0.33
MSM 1.111 0.898, 1.374 0.33
Stroke
Published ITT 0.83 0.69, 0.99 0.04
Crude ITT Logistic 0.816 0.682, 0.977 0.027
Adjusted As-Treated 0.878 0.726, 1.062 0.18
MSM 0.843 0.689, 1.031 0.096
CVD Mortality
Published ITT 0.95 0.74, 1.22 0.68
Crude ITT Logistic 0.947 0.737, 1.216 0.67
Adjusted As-Treated 0.883 0.667, 1.169 0.38
MSM 0.764 0.540, 1.081 0.13
a
Crude = adjusted for age and race, except for CVD mortality which has age only due to small numbers. The adjusted as-treated model controls for
time-varying risk factors and intervening events as specified in Table 1.






























































































































































































































































































































































































































































































































































Cook et al. Page 14
Table 5
Estimated Effects of Aspirin on CVD by Age Groups.
RR CI P P interaction
Major CVD
ITT Logistic
   45–64 yrs 0.968 0.839, 1.116 0.65 0.069
   65+ yrs 0.772 0.624, 0.956 0.018
Adjusted As-Treated
   45–64 yrs 1.047 0.901, 1.216 0.55 0.017
   65+ yrs 0.765 0.608, 0.962 0.022
MSM
   45–64 yrs 1.031 0.883, 1.202 0.71 0.010
   65+ yrs 0.725 0.570, 0.923 0.009
MI
ITT Logistic
   45–64 yrs 1.153 0.923, 1.440 0.21 0.017
   65+ yrs 0.694 0.476, 1.012 0.058
Adjusted As-Treated
   45–64 yrs 1.226 0.974, 1.544 0.083 0.062
   65+ yrs 0.819 0.556, 1.205 0.31
MSM
   45–64 yrs 1.254 0.993, 1.584 0.057 0.027
   65+ yrs 0.762 0.509, 1.141 0.19
Stroke
ITT Logistic
   45–64 yrs 0.799 0.648, 0.985 0.035 0.69
   65+ yrs 0.858 0.635, 1.159 0.32
Adjusted As-Treated
   45–64 yrs 0.911 0.732, 1.134 0.40 0.51
   65+ yrs 0.806 0.584, 1.111 0.19
MSM
   45–64 yrs 0.873 0.696, 1.096 0.24 0.54
   65+ yrs 0.776 0.550, 1.093 0.15
CVD Mortality
ITT Logistic
   45–64 yrs 0.947 0.689, 1.301 0.74 0.75
   65+ yrs 0.879 0.600, 1.286 0.51
Adjusted As-Treated
   45–64 yrs 0.830 0.575, 1.198 0.32 0.84
   65+ yrs 0.874 0.580, 1.318 0.52
MSM (120+/yr)
   45–64 yrs 0.852 0.586, 1.240 0.40 0.43
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RR CI P P interaction
   65+ yrs 0.659 0.375, 1.159 0.15













Cook et al. Page 16
Table 6
Meta-Analysis for CVD Mortality.
RR CI P
Published ITT
   PHS 0.96 0.60, 1.54 0.87
   WHS 0.95 0.74, 1.22 0.67
   Combined PHS & WHS 0.95 0.76, 1.19 0.66
As-Treated (120+/yr)
   PHS 0.81 0.57, 1.15 0.24
   WHS 0.88 0.67, 1.17 0.38
   Combined PHS & WHS 0.85 0.69, 1.06 0.16
MSM (120+/yr)
   PHS 0.74 0.48, 1.15 0.18
   WHS 0.76 0.54, 1.08 0.13
   Combined PHS & WHS 0.75 0.57, 0.99 0.042
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